Articles by tag: verve-102

CRISPR therapy VERVE-102 reduces cholesterol by 62% after injection

Journal NEJM published data on the drug VERVE-102: a single CRISPR injection (base editing) reduces LDL by 62% for 18 months without serious side effects. Learn details about the revolutionary therapy.

Cholesterol gene therapy VERVE-102: NEJM data, LDL reduction by 62%

NEJM published phase 1b results of gene therapy VERVE-102: LDL reduction by 62% after a single injection. Analysis of efficacy, risks, and prospects for patients with hypercholesterolemia. Read more.